CHMP2A Antikörper (AA 1-100)

Produktnummer ABIN2559687

Produktdetails anti-CHMP2A Antikörper

Target: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Bindungsspezifität: AA 1-100

Reaktivität: Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CHMP2A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Ratte

Homologie: Human,Mouse,Dog,Sheep

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human CHMP2A

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu CHMP2A

Target: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Andere Bezeichnung: CHMP2A (CHMP2A Produkte)

Hintergrund:

Synonyms: BC2, BC-2, VPS2, CHMP2, VPS2A, Charged multivesicular body protein 2a, Chromatin-modifying protein 2a, CHMP2a, Putative breast adenocarcinoma marker BC-2, Vacuolar protein sorting-associated protein 2-1, Vps2-1, hVps2-1

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.

Gen-ID: 27243

UniProt: O43633

Pathways: SARS-CoV-2 Protein Interaktom